Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases

Autor: Joost R. M. van der Sijp, Otilia Dalesio, Erikv van Werkhoven, Sander B. Schouten, Inne H.M. Borel Rinkes, Nikol Snoeren, Andre M. Bergman, Richard van Hillegersberg, Rob A. E. M. Tollenaar, Emile E. Voest, Henk M.W. Verheul

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 2, Pp 93-99 (2017)
Neoplasia (United States), 19(2), 93-99. Elsevier Inc.
Neoplasia, 19(2), 93-99
Snoeren, N, van Hillegersberg, R, Schouten, S B, Bergman, A M, van Werkhoven, E, Dalesio, O, Tollenaar, R A E M, Verheul, H M, van der Sijp, J, Borel Rinkes, I H M, Voest, E E & Hepatica study group 2017, ' Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases : HEPATICA study ', Neoplasia (United States), vol. 19, no. 2, pp. 93-99 . https://doi.org/10.1016/j.neo.2016.08.010

Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Recurrence after resection of colorectal liver metastases (CRLMs), presumably caused by VEGF-mediated outgrowth of micrometastases, might decrease whe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54dbb78442f192dfe55b592b0619b4a
http://www.scopus.com/inward/record.url?scp=85016028530&partnerID=8YFLogxK

Does Rectal Mucosal Blood Flow Affect the Outcome of Transanal Advancement Flap Repair?

Autor: David D. E. Zimmerman, Martijn P. Gosselink, D. M. J. Oom, Sander B. Schouten, W. Rudolph Schouten, Litza E. Mitalas

Publikováno v: Diseases of the Colon & Rectum, 52(8), 1395-1399. Lippincott Williams & Wilkins

INTRODUCTION: Transanal advancement flap repair provides a useful tool for the treatment of high transsphincteric fistulas. Recent studies indicate that transanal advancement flap repair fails in one of every three patients. Until now no definite ris

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67048b9cabd8a1938c9b9ee7837cdb22
https://doi.org/10.1007/dcr.0b013e3181a7b61e

The Thrust Plate Prosthesis: long-term clinical and radiological results

Autor: Leon W, Diederix, Peter J T S, Van Winterswijk, Sander B, Schouten, Pieter A G M, Bakx, Jaap, Huij

Publikováno v: Acta orthopaedica Belgica. 79(3)

The Thrust Plate Prosthesis is a femoral implant designed for total hip arthroplasty, based on the principles of physiologic loading of the metaphysis of the proximal femur, and preserving the bone stock. This study presents the long-term clinical an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aca10746d0850db8f4a7854a5b18b1ce
https://pubmed.ncbi.nlm.nih.gov/23926732

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

Autor: Otilia Dalesio, Emile E. Voest, R. van Hillegersberg, Sander B. Schouten, Nikol Snoeren, Henk M.W. Verheul, Andre M. Bergman, Rob A. E. M. Tollenaar, Inne H.M. Borel Rinkes, Joost R. M. van der Sijp

Publikováno v: BMC Cancer
BMC Cancer, 10. BioMed Central
Snoeren, N, Voest, E E, Bergman, A, Dalesio, O, Verheul, H M W, Tollenaar, R A E M, van der Sijp, J R, Schouten, S B, Rinkes, I H M B & van Hillegersberg, R 2010, ' A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment ', BMC Cancer, vol. 10, pp. 545 . https://doi.org/10.1186/1471-2407-10-545
BMC Cancer, Vol 10, Iss 1, p 545 (2010)

Background About 50% of patients with colorectal cancer are destined to develop hepatic metastases. Radical resection is the most effective treatment for patients with colorectal liver metastases offering five year survival rates between 36-60%. Unfo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aaaf363cfaa037390bc5e794c9b3aa6
http://europepmc.org/articles/PMC2958953